Larry J. Copeland, MD, discusses the importance of germline testing in ovarian cancer.
Larry J. Copeland, MD
Advertisement
Articles by Larry J. Copeland, MD
Larry J. Copeland, MD, discusses the prevalence of ovarian cancer in the United States.
Larry J. Copeland, MD, professor, Obstetrics & Gynecology, College of Medicine, The Ohio State University Comprehensive Cancer Center–James, discusses the use of PARP inhibitors in ovarian cancer.
Larry J. Copeland, MD, discusses the role of chemotherapy in ovarian cancer.
Larry J. Copeland, MD, discusses the etiology of ovarian cancer.
Advertisement
Latest Updated Articles
Dr. Copeland on the Etiology of Ovarian CancerPublished: November 21st 2019 | Updated:
Dr. Copeland on the Role of Chemotherapy in Ovarian CancerPublished: January 18th 2020 | Updated:
Dr. Copeland on the Use of PARP Inhibitors in Ovarian CancerPublished: February 11th 2020 | Updated:
Dr. Copeland on the Prevalence of Ovarian Cancer in the United StatesPublished: February 25th 2020 | Updated:
Dr. Copeland on the Importance of Germline Testing in Ovarian CancerPublished: March 26th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
5